busulfan has been researched along with Primary Immunodeficiency Diseases in 6 studies
Primary Immunodeficiency Diseases: Genetic immunologic deficiency diseases and syndromes due to mutations in genes involved in IMMUNITY generally characterized by an increased susceptibility to infectious diseases. They are often associated with AUTOIMMUNE DISEASE manifestations.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of our study was to compare the safety and efficacy of hematopoietic cell transplantation (HCT) using fludarabine (Flu)-based reduced intensity conditioning (RIC) with busulfan (BU) or melphalan (Mel) for primary immunodeficiency diseases (PID)." | 8.02 | Hematopoietic Cell Transplantation with Reduced Intensity Conditioning Using Fludarabine/Busulfan or Fludarabine/Melphalan for Primary Immunodeficiency Diseases. ( Aoki, Y; Ashiarai, M; Endo, A; Hiroki, H; Hoshino, A; Ichimura, T; Imai, K; Inoue, K; Inoue, M; Ishiwata, Y; Isoda, T; Kajiwara, M; Kamiya, T; Kanegane, H; Kawahara, Y; Matsumoto, K; Mitsuiki, N; Miyamoto, S; Miyawaki, R; Mizutani, S; Morio, T; Nagasawa, M; Nishimura, A; Okano, T; Okawa, T; Ono, S; Ono, T; Takagi, M; Tanaka-Kubota, M; Tezuka, M; Tomizawa, D; Tomoda, T; Ueyama, J; Yamagishi, C; Yamashita, M; Yanagimachi, M; Yasuhara, M, 2021) |
| "We report three adult patients with primary immunodeficiency (PID) treated with reduced-intensity allogenic hematopoietic cell transplantation (HCT) with fludarabine/treosulfan conditioning and graft-versus-host disease (GvHD) prophylaxis with alemtuzumab and a calcineurin inhibitor." | 4.12 | Treosulfan-based Reduced-intensity Allogeneic Hematopoietic Cell Transplantation in Adults With Primary Immunodeficiency: A Case Series. ( Arranto, C; Dalla Via, V; Heim, D; Junker, T; Matteazzi, F; Medinger, M; Passweg, JR; Recher, M; Stelmes, A; van den Berg, J, 2022) |
| "The purpose of our study was to compare the safety and efficacy of hematopoietic cell transplantation (HCT) using fludarabine (Flu)-based reduced intensity conditioning (RIC) with busulfan (BU) or melphalan (Mel) for primary immunodeficiency diseases (PID)." | 4.02 | Hematopoietic Cell Transplantation with Reduced Intensity Conditioning Using Fludarabine/Busulfan or Fludarabine/Melphalan for Primary Immunodeficiency Diseases. ( Aoki, Y; Ashiarai, M; Endo, A; Hiroki, H; Hoshino, A; Ichimura, T; Imai, K; Inoue, K; Inoue, M; Ishiwata, Y; Isoda, T; Kajiwara, M; Kamiya, T; Kanegane, H; Kawahara, Y; Matsumoto, K; Mitsuiki, N; Miyamoto, S; Miyawaki, R; Mizutani, S; Morio, T; Nagasawa, M; Nishimura, A; Okano, T; Okawa, T; Ono, S; Ono, T; Takagi, M; Tanaka-Kubota, M; Tezuka, M; Tomizawa, D; Tomoda, T; Ueyama, J; Yamagishi, C; Yamashita, M; Yanagimachi, M; Yasuhara, M, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 4 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Dalla Via, V | 1 |
| Stelmes, A | 1 |
| Recher, M | 1 |
| Arranto, C | 1 |
| Junker, T | 1 |
| Matteazzi, F | 1 |
| Heim, D | 1 |
| Passweg, JR | 1 |
| Medinger, M | 1 |
| van den Berg, J | 1 |
| Yu, ZP | 1 |
| Ding, JH | 1 |
| Sun, AN | 1 |
| Chen, BA | 1 |
| Ge, Z | 1 |
| Wu, DP | 1 |
| Dimitrova, D | 1 |
| Gea-Banacloche, J | 1 |
| Steinberg, SM | 1 |
| Sadler, JL | 1 |
| Hicks, SN | 1 |
| Carroll, E | 1 |
| Wilder, JS | 1 |
| Parta, M | 1 |
| Skeffington, L | 1 |
| Hughes, TE | 1 |
| Blau, JE | 1 |
| Broadney, MM | 1 |
| Rose, JJ | 1 |
| Hsu, AP | 1 |
| Fletcher, R | 1 |
| Nunes, NS | 1 |
| Yan, XY | 1 |
| Telford, WG | 1 |
| Kapoor, V | 1 |
| Cohen, JI | 1 |
| Freeman, AF | 1 |
| Garabedian, E | 1 |
| Holland, SM | 1 |
| Lisco, A | 1 |
| Malech, HL | 1 |
| Notarangelo, LD | 1 |
| Sereti, I | 1 |
| Shah, NN | 1 |
| Uzel, G | 1 |
| Zerbe, CS | 1 |
| Fowler, DH | 1 |
| Gress, RE | 1 |
| Kanakry, CG | 1 |
| Kanakry, JA | 1 |
| Lum, SH | 1 |
| Hoenig, M | 1 |
| Gennery, AR | 1 |
| Slatter, MA | 1 |
| Al-Mofareh, M | 1 |
| Ayas, M | 1 |
| Al-Seraihy, A | 1 |
| Siddiqui, K | 1 |
| Al-Jefri, A | 1 |
| Ghemlas, I | 1 |
| Alsaedi, H | 1 |
| El-Solh, H | 1 |
| Al-Sweedan, S | 1 |
| Al-Saud, B | 1 |
| Al-Mousa, H | 1 |
| Al-Dhekri, H | 1 |
| Arnaout, R | 1 |
| Mohammed, R | 1 |
| Al-Muhsen, S | 1 |
| Al-Ahmari, A | 1 |
| Nishimura, A | 1 |
| Aoki, Y | 1 |
| Ishiwata, Y | 1 |
| Ichimura, T | 1 |
| Ueyama, J | 1 |
| Kawahara, Y | 1 |
| Tomoda, T | 1 |
| Inoue, M | 1 |
| Matsumoto, K | 1 |
| Inoue, K | 1 |
| Hiroki, H | 1 |
| Ono, S | 1 |
| Yamashita, M | 1 |
| Okano, T | 1 |
| Tanaka-Kubota, M | 1 |
| Ashiarai, M | 1 |
| Miyamoto, S | 1 |
| Miyawaki, R | 1 |
| Yamagishi, C | 1 |
| Tezuka, M | 1 |
| Okawa, T | 1 |
| Hoshino, A | 1 |
| Endo, A | 1 |
| Yasuhara, M | 1 |
| Kamiya, T | 1 |
| Mitsuiki, N | 1 |
| Ono, T | 1 |
| Isoda, T | 1 |
| Yanagimachi, M | 1 |
| Tomizawa, D | 1 |
| Nagasawa, M | 1 |
| Mizutani, S | 1 |
| Kajiwara, M | 1 |
| Takagi, M | 1 |
| Kanegane, H | 1 |
| Imai, K | 1 |
| Morio, T | 1 |
1 review available for busulfan and Primary Immunodeficiency Diseases
| Article | Year |
|---|---|
Conditioning Regimens for Hematopoietic Cell Transplantation in Primary Immunodeficiency.
Topics: Busulfan; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Primary Immunod | 2019 |
1 trial available for busulfan and Primary Immunodeficiency Diseases
| Article | Year |
|---|---|
Prospective Study of a Novel, Radiation-Free, Reduced-Intensity Bone Marrow Transplantation Platform for Primary Immunodeficiency Diseases.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; | 2020 |
4 other studies available for busulfan and Primary Immunodeficiency Diseases
| Article | Year |
|---|---|
Treosulfan-based Reduced-intensity Allogeneic Hematopoietic Cell Transplantation in Adults With Primary Immunodeficiency: A Case Series.
Topics: Adult; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Mal | 2022 |
A New Conditioning Regimen Can Significantly Promote Post-Transplant Immune Reconstitution and Improve the Outcome of Umbilical Cord Blood Transplantation for Patients.
Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busul | 2019 |
Hematopoietic stem cell transplantation in children with Griscelli syndrome type 2: a single-center report on 35 patients.
Topics: Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphohisti | 2020 |
Hematopoietic Cell Transplantation with Reduced Intensity Conditioning Using Fludarabine/Busulfan or Fludarabine/Melphalan for Primary Immunodeficiency Diseases.
Topics: Busulfan; Child, Preschool; Drug Combinations; Female; Graft vs Host Disease; Hematopoietic Stem Cel | 2021 |